Grand Brilliance Group Holdings Limited (HK:8372)
:8372
Top Page
Grand Brilliance Group Holdings Limited
(8372)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$0.14
▲(16.67% Upside)
Action:DowngradedDate:12/09/25
The stock is supported by strong financial performance and a solid valuation, with a reasonable P/E ratio and dividend yield. However, technical indicators suggest caution due to overbought conditions. The lack of earnings call and corporate events data limits further insights.
Positive Factors
Low Leverage / Strong Balance Sheet
A debt-to-equity of 0.035 indicates very low leverage, giving durable financial flexibility to fund operations, absorb shocks, pursue selective M&A or capex, and maintain dividends without reliance on volatile capital markets over the next 2-6 months.
Negative Factors
Sharp Decline in Free Cash Flow Growth
An 87% drop in free cash flow growth is a material structural concern: it constrains discretionary spending, weakens the ability to invest or sustain dividends, and heightens reliance on working capital management or external financing in the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
A debt-to-equity of 0.035 indicates very low leverage, giving durable financial flexibility to fund operations, absorb shocks, pursue selective M&A or capex, and maintain dividends without reliance on volatile capital markets over the next 2-6 months.
Read all positive factors
Grand Brilliance Group Holdings Limited (8372) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$104.80M
Dividend Yield1.89%
Average Volume (3M)70.67K
Price to Earnings (P/E)5.4
Beta (1Y)-0.02
Revenue Growth27.91%
EPS Growth18.87%
CountryHK
Employees50
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)<0.01
Shares Outstanding800,000,000
10 Day Avg. Volume4,000
30 Day Avg. Volume70,666
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.78
Price to Sales (P/S)0.91
P/FCF Ratio73.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Grand Brilliance Group Holdings Limited Business Overview & Revenue Model
Company Description
Grand Brilliance Group Holdings Limited, an investment holding company, engages in supplying of medical devices in Hong Kong. It offers medical consumables; medical instruments; and medical equipment, as well as develops healthcare products. The c...
How the Company Makes Money
null...
Grand Brilliance Group Holdings Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 105.25M | 94.45M | 81.90M | 76.70M | 71.98M | 70.24M |
| Gross Profit | 45.52M | 45.72M | 41.94M | 39.51M | 36.35M | 33.62M |
| EBITDA | 10.41M | 13.95M | 13.20M | 14.09M | 9.87M | 12.91M |
| Net Income | 10.07M | 9.46M | 7.86M | 7.56M | 4.05M | 7.86M |
Balance Sheet | ||||||
| Total Assets | 137.53M | 132.19M | 114.50M | 115.25M | 110.32M | 112.01M |
| Cash, Cash Equivalents and Short-Term Investments | 53.86M | 60.96M | 60.47M | 61.86M | 55.74M | 70.26M |
| Total Debt | 3.06M | 3.91M | 1.43M | 4.45M | 4.48M | 4.87M |
| Total Liabilities | 24.20M | 20.75M | 11.22M | 16.58M | 16.82M | 18.96M |
| Stockholders Equity | 112.83M | 110.79M | 103.33M | 98.67M | 93.51M | 93.05M |
Cash Flow | ||||||
| Free Cash Flow | -3.77M | 1.17M | 4.91M | 12.60M | -4.12M | 5.62M |
| Operating Cash Flow | -3.58M | 1.35M | 6.72M | 12.66M | -3.33M | 6.01M |
| Investing Cash Flow | 3.67M | 3.77M | -395.00K | -510.00K | -3.96M | -82.00K |
| Financing Cash Flow | -4.93M | -4.87M | -7.42M | -6.40M | -7.58M | -6.36M |
Grand Brilliance Group Holdings Limited Technical Analysis
Neutral
0.12
Price Trends
0.13
Negative
0.13
Positive
0.12
Positive
Market Momentum
>-0.01
Positive
40.84
Neutral
17.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8372, the sentiment is Neutral. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.13, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.84 is Neutral, neither overbought nor oversold. The STOCH value of 17.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:8372.
Grand Brilliance Group Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$104.80M | 5.39 | 10.73% | 1.89% | 27.91% | 18.87% | |
54 Neutral | HK$126.61M | -18.49 | -17.12% | ― | -4.50% | 75.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$721.31M | -5.63 | 476.63% | ― | -17.39% | -45.76% | |
40 Underperform | HK$157.50M | -0.48 | ― | ― | -20.78% | 6.78% |
* Healthcare Sector Average
HK:8372
Grand Brilliance Group Holdings Limited
0.13
0.03
35.05%
HK:0673
China Health Group
0.52
0.36
225.00%
HK:0718
Tai United Holdings
0.03
<0.01
15.38%
HK:0401
Wanjia Group Holdings Ltd.
0.11
0.07
151.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.